Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy-Reference-Cited by-同舟云学术

Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy

Published:2017-10-31 Issue:12 Volume:14 Page:
ISSN:1570-1808
Container-title:Letters in Drug Design & Discovery
language:en
Short-container-title:LDDD

Author:

Munoz Miguel¹,Rosso Marisa²,Covenas Rafael³

Affiliation:

1. Hospital Infantil Virgen del Rocio, Unidad de Cuidados Intensivos Pediatricos, Av. Manuel Siurot s/n, 41013-Sevilla, Spain

2. Research Laboratory on Neuropeptides (IBIS), Virgen del Rocio University Hospital, Sevilla, Spain

3. Institute of Neurosciences of Castilla y Leon (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems, University of Salamanca, Salamanca, Spain

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term Use of Angiotensin-converting Enzyme Inhibitors Increases Substance P Levels, Which is Involved in the Risk of Lung Cancer;Archivos de Bronconeumología;2023-12

2. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant;International Journal of Molecular Sciences;2023-11-03

3. Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions;Expert Review of Clinical Pharmacology;2022-12-28

4. Neurokinin-1 Receptor Antagonists as Anticancer Drugs;Letters in Drug Design & Discovery;2019-09-19

5. Neurokinin‑1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report;Molecular and Clinical Oncology;2019-05-10